Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Judson

Showing results (81-90 of 151) with videos related to

Pageof 16
Sort By:
Anticancer Research|July 2, 2014
A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experienceCharlotte Benson, Joanna Vitfell-Rasmussen, Marco Maruzzo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2009
Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)Alessandro Gronchi, Ian Judson, Toshirou Nishida, et al.
Investigational New Drugs|October 8, 2010
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumorsLaura Vidal, Margarita Magem, Clare Barlow, et al.
Gynecologic Oncology|September 16, 2011
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centersRoberta Sanfilippo, Federica Grosso, Robin L Jones, et al.
Clinical Sarcoma Research|May 20, 2015
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcomaBeatrice Seddon, Michelle Scurr, Robin L Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2004
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupIan Judson, Peiming Ma, Bin Peng, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2016
Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entityMyrella Vlenterie, Saskia Litière, Elisa Rizzo, et al.
Clinical Sarcoma Research|April 30, 2015
First line palliative chemotherapy in elderly patients with advanced soft tissue sarcomaNadia Yousaf, Samuel Harris, Juan Martin-Liberal, et al.
Cancers|June 24, 2022
Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous LeiomyomatosisLukas Krasny, Chris P Wilding, Emma Perkins, et al.
Pageof 16

Showing results (81-90 of 151) with videos related to

Sort By:
Pageof 16
Anticancer Research|July 2, 2014
A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experienceCharlotte Benson, Joanna Vitfell-Rasmussen, Marco Maruzzo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2009
Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)Alessandro Gronchi, Ian Judson, Toshirou Nishida, et al.
Investigational New Drugs|October 8, 2010
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumorsLaura Vidal, Margarita Magem, Clare Barlow, et al.
Gynecologic Oncology|September 16, 2011
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centersRoberta Sanfilippo, Federica Grosso, Robin L Jones, et al.
Clinical Sarcoma Research|May 20, 2015
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcomaBeatrice Seddon, Michelle Scurr, Robin L Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2004
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupIan Judson, Peiming Ma, Bin Peng, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2016
Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entityMyrella Vlenterie, Saskia Litière, Elisa Rizzo, et al.
Clinical Sarcoma Research|April 30, 2015
First line palliative chemotherapy in elderly patients with advanced soft tissue sarcomaNadia Yousaf, Samuel Harris, Juan Martin-Liberal, et al.
Cancers|June 24, 2022
Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous LeiomyomatosisLukas Krasny, Chris P Wilding, Emma Perkins, et al.
Pageof 16